10-Q: Tharimmune Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Tharimmune Inc. reported a net loss of $2.26 million for the first quarter of 2024, while advancing its clinical and preclinical programs.

Summary

• Tharimmune Inc. reported a net loss of $2.26 million for the first quarter of 2024, compared to a net loss of $2.69 million for the same period in 2023.
• The company's operating expenses totaled $2.35 million, with research and development expenses at $1.03 million and general and administrative expenses at $1.32 million.
• Cash and cash equivalents decreased to $8.43 million as of March 31, 2024, from $10.94 million at the end of 2023.
• The company has an accumulated deficit of approximately $27.0 million as of March 31, 2024.
• Tharimmune is focused on developing therapeutic candidates in immunology and inflammation, including TH104 for chronic pruritis and several immuno-oncology candidates.
• The company completed a Phase 1 clinical trial for TH104, with full data expected in the second quarter of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and pipeline development, the financial situation is concerning with a significant net loss, decreasing cash balance, and a going concern warning. This suggests a cautious outlook.

Positives

• The net loss decreased by $0.43 million compared to the same quarter last year.
• The company completed a Phase 1 clinical trial for TH104 with positive safety and tolerability results.
• The company is progressing multiple therapeutic candidates into IND-enabling studies.
• The company secured an exclusive license for TH104 and TH103.

Negatives

• The company experienced a net loss of $2.26 million for the quarter.
• The company's cash balance decreased by $2.5 million during the quarter.
• The company has an accumulated deficit of $27.0 million.
• The company has a going concern warning due to recurring losses and the need for additional funding.

Risks

• The company has a limited operating history and recurring negative cash flows.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company needs substantial additional funding to support future operations.
• Failure to obtain sufficient funding could adversely affect the company's ability to achieve its business objectives and product development timelines.
• The company is subject to risks common to biopharmaceutical companies, including dependence on key personnel, protection of proprietary technology, and compliance with government regulations.
• The company is dependent on third-party suppliers.
• There is no assurance that the company's products will receive required regulatory approvals.

Future Outlook

The company anticipates that TH3215, TH0059, and TH1940 will progress to enter IND-enabling studies in 2024 and 2025. The company also plans to pursue strategic collaboration opportunities to maximize the value of its pipeline.

Management Comments

• The company is focused on developing therapeutic candidates in immunology and inflammation with high unmet need.
• The company intends to first seek approval for TH104 for the treatment of moderate to severe chronic pruritis in patients with primary biliary cholangitis (PBC).
• The company is advancing TH3215, a bispecific antibody, into IND-enabling studies in 2024.
• The company is also developing TH0059, a bispecific ADC, and TH1940, a PD-1 Picobody, for IND-enabling studies in 2024.

Industry Context

The company is operating in the competitive biotechnology sector, focusing on novel therapeutics for unmet medical needs in immunology, inflammation, and oncology. The company's focus on bispecific antibodies, ADCs, and Picobodies aligns with current trends in drug development.

Comparison to Industry Standards

• The company's cash burn rate of approximately $2.8 million for the quarter is typical for a clinical-stage biotech company.
• The company's focus on novel therapeutic modalities such as bispecific antibodies and Picobodies is consistent with industry trends.
• The company's pipeline is focused on high-value targets such as HER2, HER3, and PD-1, which are common targets in the immuno-oncology space.
• The company's development of TH104 for chronic pruritis in PBC addresses a rare disease with a high unmet need, similar to other companies focusing on orphan drug development.

Stakeholder Impact

• Shareholders are impacted by the company's net loss and the going concern warning.
• Employees are impacted by the company's financial situation and the need for additional funding.
• Customers (potential patients) are impacted by the company's progress in developing new therapies.
• Suppliers are impacted by the company's ability to pay for services and materials.

Next Steps

• The company expects full data from the Phase 1 clinical trial of TH104 in the second quarter of 2024.
• The company plans to advance TH3215, TH0059, and TH1940 into IND-enabling studies in 2024 and 2025.
• The company will continue to pursue strategic collaboration opportunities.

Key Dates

Keywords

biotechnology, clinical-stage, immunology, inflammation, immuno-oncology, TH104, TH3215, TH0059, TH1940, pruritis, HER2, HER3, PD-1, IND, clinical trials